Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 601 - 625 of 14988 in total

Iopromide

Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can cause several serious adverse effects, including...
Approved
Matched Description: … [A260751] Although the mechanism is unclear, women and outpatients tend to have a higher incidence of ... several serious adverse effects, including cardiac events, thromboembolism, hypersensitivity reaction, and ... brain computer tomography (CT), coronary arteriography, left ventriculography, visceral angiography, and …

Tremelimumab

Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours...
Approved
Investigational
Matched Description: … [A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces ... investigated in other cancers, such as colon cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Monoclonal antibodies and antibody drug conjugates …

Lanreotide

Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, Ipsen...
Approved
Matched Description: … It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. ... Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Somatostatin and Analogues ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Lutetium Lu 177 dotatate

A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as...
Approved
Investigational
Matched Description: … Targeting pancreas and other parts of the gastrointestinal tract such as the intestines and colon, neuroendocrine ... tumors may commonly metastasize to metastasize to the mesentery, peritoneum, and liver [A31697]. ... The presence of a radioligand allows monitoring of treatment response post therapy and prior to next …
Matched Categories: … Indicators and Reagents ... Somatostatin and Analogues ... Amino Acids, Peptides, and Proteins …

Tafasitamab

Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19...
Approved
Investigational
Matched Description: … results in the lysis of B-cells (both healthy and malignant). ... [L15302] It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains ... [L15292] Having previously received Breakthrough Therapy, Fast Track, and Orphan designations from …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Monoclonal antibodies and antibody drug conjugates …

Glatiramer

Glatiramer acetate is a mix of synthetic polypeptides that includes L-glutamic acid, L-alanine, L-tyrosine, and L-lysine at an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. Since glatiramer acetate is a heterogeneous drug, there is limited information about its physicochemical properties. Originally, glatiramer acetate was designed as a...
Approved
Investigational
Matched Description: … L-lysine at an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. ... [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. ... Glatiramer acetate is a mix of synthetic polypeptides that includes L-glutamic acid, L-alanine, L-tyrosine, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Polistes annularis venom protein

Polistes annularis venom protein is an extract of Polistes annularis venom. Polistes annularis venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …

Olaratumab

Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the...
Approved
Investigational
Matched Description: … It is composed of two heavy chain molecule fragments and 2 light chain fragments. ... binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and ... olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Monoclonal antibodies and antibody drug conjugates …

Triheptanoin

Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly.[A214812,A214817] Complications in lc-FAOD patients...
Approved
Investigational
Matched Description: … treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Pramlintide

Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Approved
Investigational
Matched Description: … Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Asfotase alfa

Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). Hypophosphatasia is almost always fatal when severe skeletal disease is obvious at birth. By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels...
Approved
Investigational
Matched Description: … morbidity and premature death. ... Food and Drug Administration (FDA) on October 23, 2015. ... 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved by …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Teclistamab

Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds,[A253587, L43622] allowing the drug...
Approved
Investigational
Matched Description: … is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and ... [A253587] Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Monoclonal antibodies and antibody drug conjugates …

Lumacaftor

Lumacaftor is a drug used in combination with DB08820 as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic...
Approved
Matched Description: … sodium ions across cell membranes of the lungs, pancreas, and other organs. ... Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016 ... and trafficking of mature protein to the cell surface. …
Matched Categories: … ivacaftor and lumacaftor …

Alglucerase

Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated...
Approved
Investigational
Withdrawn
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Racephedrine

Approved
Experimental
Matched Categories: … Herbs and Natural Products ... Alpha-and Beta-adrenergic Agonists …

Ademetionine

Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)
Approved
Investigational
Nutraceutical
Matched Description: … Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all ... It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. …
Matched Categories: … Amino Acids and Derivatives ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Nucleic Acids, Nucleotides, and Nucleosides …

Lisocabtagene maraleucel

Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to brexucabtagene autoleucel and axicabtagene ciloleucel.[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing survival rates over standard...
Approved
Matched Description: … maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and ... [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Tilactase

Tilactase is a beta-D-galactosidase obtained from Aspergillus oryzae. It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal. The beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8-barrel domain. It is considered by the WHO...
Approved
Experimental
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Tenofovir alafenamide

Tenofovir alafenamide is a novel tenofovir prodrug developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil. Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal...
Approved
Matched Description: … group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and ... [L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval ... alafenamide is indicated to treat chronic hepatitis B,[L6241] treat HIV-1,[L4388,L6277,L6280,L6283] and …
Matched Categories: … Tenofovir and prodrugs ... Amino Acids, Peptides, and Proteins ... emtricitabine and tenofovir alafenamide ... emtricitabine, tenofovir alafenamide and rilpivirine ... emtricitabine, tenofovir alafenamide and bictegravir …

Lumasiran

Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1). This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. These patients experience frequent kidney stones, nephrocalcinosis, and renal failure. Oxlumo, producted by...
Approved
Investigational
Matched Description: … [L23554] These patients experience frequent kidney stones, nephrocalcinosis, and renal failure. ... consisted of symptomatic treatment such as hyperhydration, inhibitors of crystallization, [pyridoxine], and …
Matched Salts name: … Lumasiran sodium …
Matched Categories: … Alimentary Tract and Metabolism ... Nucleic Acids, Nucleotides, and Nucleosides ... Various Alimentary Tract and Metabolism Products …

Technetium Tc-99m sulfur colloid

Technetium 99m sulfur colloid is a radiopharmaceutical diagnostic agent used in the evaluation of various conditions including lymph node metastases in breast cancer, detection of shunt patency, imaging of reticuloendothelial cells for assessment of liver function, and studies of esophageal transit and gastroesophageal reflux. Following injection or oral administration, single...
Approved
Investigational
Matched Description: … studies of esophageal transit and gastroesophageal reflux. ... detection of shunt patency, imaging of reticuloendothelial cells for assessment of liver function, and ... Depending on site of administration and intended usage, Technetium 99m sulfur colloid enters the capillaries …
Matched Categories: … Indicators and Reagents ... Hepatic and Reticulo Endothelial System ... Technetium (99Mtc), Particles and Colloids …

Epoetin delta

Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
Approved
Investigational
Withdrawn
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Risankizumab

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab...
Approved
Investigational
Matched Description: … [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. ... It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …

Mosunetuzumab

Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody. It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as...
Approved
Investigational
Matched Description: … [L42230] It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 ... unlike CAR-T therapies such as [axicabtagene ciloleucel] and [tisagenlecleucel], it is an “off-the-shelf ... potential to circumvent resistance to [rituximab] in patients with follicular lymphoma,[A249320,L42230] and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Monoclonal antibodies and antibody drug conjugates …

Asparaginase Escherichia coli

Asparaginase derived from Escherichia coli (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from E. coli has clinically shown to exhibit antitumor...
Approved
Investigational
Matched Description: … enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and …
Matched Categories: … Enzymes and Coenzymes ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 601 - 625 of 14988 in total